Page 19 - Core One News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Plant-Based Investment Corp.: PBIC To Rescind Share Exchange With Core One Labs Company") ( Core One") to rescind the share exchange transaction previously completed between the parties (the " Share Exchange"). Effective March 16, 2020, the Company subscribed for and acquired 5,333,333 common shares of Core One (or 2,666,667 common shares of Core One after giving effect to Core One's share consolidation completed on July 8, 2020), and in consideration issued 3,149,606 common shares of PBIC to Core One. The Company and Core One have agreed to rescind the Share Exchange and return to treasury a...

Press release content from Accesswire. The AP news staff was not involved in its creation. Core One Labs to Rescind Share Exchange with Plant-Based Investment Corp. April 15, 2021 GMT VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the "Company" or "Core One") announces that it has reached an agreement with Plant-Based Investment Corp. (formerly, Cannabis Growth ... VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the "Company" or "Core One") announces that it h...

Core One Labs Inc.: Core One Labs Vocan Expands Product Commercialization Team Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the " Company" or " Core One") is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. (" Vocan") has expanded its product commercialization team, adding Dr. Elizabeth Matthews as Head of Scientific and Regulatory Affairs. Dr. Matthews will oversee research and development, as well as the commercialization of Vocan's new product offerings, including the navigation of regulatory processes involved during transition fro...

Core One Labs Inc.: Core One Labs Initiates First Strain Production for Biosynthetic Psilocybin VANCOUVER, BC / ACCESSWIRE / February 26, 2021 / Core One Labs Inc. (CSE:COOL), (OTC PINK:CLABF), (Frankfurt:LD62, WKN: A2P8K3) (the "Company" or "Core One") a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce readiness to begin initial biosynthetic psilocybin production trials. The Company's wholly owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has successfully completed the deve...

VANCOUVER, BC / ACCESSWIRE / February 24, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62)(WKN:A2P8K3) (the "Company" or "Core One") a research and technology company focused in life